1
|
Giglio RM, Hou N, Wyatt A, Hong J, Shi L, Vaikunthan M, Fuchs H, Nima JP, Malinowski SW, Ligon KL, McFaline-Figueroa JR, Yosef N, Azizi E, McFaline-Figueroa JL. A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.04.08.587960. [PMID: 38645018 PMCID: PMC11030430 DOI: 10.1101/2024.04.08.587960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
Over-activation of the epidermal growth factor receptor (EGFR) is a hallmark of glioblastoma. However, EGFR-targeted therapies have led to minimal clinical response. While delivery of EGFR inhibitors (EGFRis) to the brain constitutes a major challenge, how additional drug-specific features alter efficacy remains poorly understood. We apply highly multiplex single-cell chemical genomics to define the molecular response of glioblastoma to EGFRis. Using a deep generative framework, we identify shared and drug-specific transcriptional programs that group EGFRis into distinct molecular classes. We identify programs that differ by the chemical properties of EGFRis, including induction of adaptive transcription and modulation of immunogenic gene expression. Finally, we demonstrate that pro-immunogenic expression changes associated with a subset of tyrphostin family EGFRis increase the ability of T-cells to target glioblastoma cells. One Sentence Summary Deep chemical genomic profiling reveals heterogeneity in response to the targeting of EGFR via myriad chemical means.
Collapse
|
2
|
Choi J, Bordeaux ZA, McKeel J, Nanni C, Sutaria N, Braun G, Davis C, Miller MN, Alphonse MP, Kwatra SG, West CE, Kwatra MM. GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma. Int J Mol Sci 2022; 23:ijms23084174. [PMID: 35456993 PMCID: PMC9030248 DOI: 10.3390/ijms23084174] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 04/06/2022] [Accepted: 04/07/2022] [Indexed: 12/13/2022] Open
Abstract
Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current standard of care is especially poor in patients with a constitutively active form of EGFR, EGFRvIII, which is associated with shorter survival time. This study examined the effect of GZ17-6.02, a novel anti-cancer agent undergoing phase 1 studies, on two EGFRvIII+ glioblastoma stem cells: D10-0171 and D317. In vitro analyses showed that GZ17-6.02 inhibited the growth of both D10-0171 and D317 cells with IC50 values of 24.84 and 28.28 µg/mL respectively. RNA sequencing and reverse phase protein array analyses revealed that GZ17-6.02 downregulates pathways primarily related to steroid synthesis and cell cycle progression. Interestingly, G17-6.02’s mechanism of action involves the downregulation of the recently identified glioblastoma super-enhancer genes WSCD1, EVOL2, and KLHDC8A. Finally, a subcutaneous xenograft model showed that GZ17-6.02 inhibits glioblastoma growth in vivo. We conclude that GZ17-6.02 is a promising combination drug effective at inhibiting the growth of a subset of glioblastomas and our data warrants further preclinical studies utilizing xenograft models to identify patients that may respond to this drug.
Collapse
Affiliation(s)
- Justin Choi
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; (J.C.); (Z.A.B.); (N.S.); (M.P.A.); (S.G.K.)
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Zachary A. Bordeaux
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; (J.C.); (Z.A.B.); (N.S.); (M.P.A.); (S.G.K.)
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Jaimie McKeel
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Cory Nanni
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Nishadh Sutaria
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; (J.C.); (Z.A.B.); (N.S.); (M.P.A.); (S.G.K.)
| | - Gabriella Braun
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Cole Davis
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Meghan N. Miller
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
| | - Martin P. Alphonse
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; (J.C.); (Z.A.B.); (N.S.); (M.P.A.); (S.G.K.)
| | - Shawn G. Kwatra
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; (J.C.); (Z.A.B.); (N.S.); (M.P.A.); (S.G.K.)
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | | | - Madan M. Kwatra
- Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; (J.M.); (C.N.); (G.B.); (C.D.); (M.N.M.)
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA
- Correspondence: ; Tel.: +1-(919)-681-4782
| |
Collapse
|
3
|
Jernigan F, Branstrom A, Baird JD, Cao L, Dali M, Furia B, Kim MJ, O'Keefe K, Kong R, Laskin OL, Colacino JM, Pykett M, Mollin A, Sheedy J, Dumble M, Moon YC, Sheridan R, Mühlethaler T, Spiegel RJ, Prota AE, Steinmetz MO, Weetall M. Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent. Mol Cancer Ther 2021; 20:1846-1857. [PMID: 34315764 PMCID: PMC9398121 DOI: 10.1158/1535-7163.mct-20-0774] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 01/20/2021] [Accepted: 06/09/2021] [Indexed: 01/07/2023]
Abstract
PTC596 is an investigational small-molecule tubulin-binding agent. Unlike other tubulin-binding agents, PTC596 is orally bioavailable and is not a P-glycoprotein substrate. So as to characterize PTC596 to position the molecule for optimal clinical development, the interactions of PTC596 with tubulin using crystallography, its spectrum of preclinical in vitro anticancer activity, and its pharmacokinetic-pharmacodynamic relationship were investigated for efficacy in multiple preclinical mouse models of leiomyosarcomas and glioblastoma. Using X-ray crystallography, it was determined that PTC596 binds to the colchicine site of tubulin with unique key interactions. PTC596 exhibited broad-spectrum anticancer activity. PTC596 showed efficacy as monotherapy and additive or synergistic efficacy in combinations in mouse models of leiomyosarcomas and glioblastoma. PTC596 demonstrated efficacy in an orthotopic model of glioblastoma under conditions where temozolomide was inactive. In a first-in-human phase I clinical trial in patients with cancer, PTC596 monotherapy drug exposures were compared with those predicted to be efficacious based on mouse models. PTC596 is currently being tested in combination with dacarbazine in a clinical trial in adults with leiomyosarcoma and in combination with radiation in a clinical trial in children with diffuse intrinsic pontine glioma.
Collapse
Affiliation(s)
| | | | - John D. Baird
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Liangxian Cao
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Mandar Dali
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Bansri Furia
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Min Jung Kim
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Kylie O'Keefe
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Ronald Kong
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | | | | | - Mark Pykett
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | - Anna Mollin
- PTC Therapeutics, Inc., South Plainfield, New Jersey
| | | | | | | | | | | | | | - Andrea E. Prota
- Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, Villigen PSI, Switzerland
| | - Michel O. Steinmetz
- University of Basel, Biozentrum, Basel, Switzerland.,Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, Villigen PSI, Switzerland
| | - Marla Weetall
- PTC Therapeutics, Inc., South Plainfield, New Jersey.,Corresponding Author: Marla Weetall, PTC Therapeutics, Inc. 100 Corporate Court, South Plainfield, NJ 07080. E-mail:
| |
Collapse
|
4
|
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC, Ballman KV, Ramakrishna R, Cross DA, Markert JM, Lim M, Gilbert MR, Lesser GJ, Kwatra MM. Efficacy of osimertinib against EGFRvIII+ glioblastoma. Oncotarget 2020; 11:2074-2082. [PMID: 32547705 PMCID: PMC7275784 DOI: 10.18632/oncotarget.27599] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 04/27/2020] [Indexed: 11/25/2022] Open
Abstract
Epidermal Growth Factor Receptor variant III (EGFRvIII) is an active mutant form of EGFR that drives tumor growth in a subset of glioblastoma (GBM). It occurs in over 20% of GBMs, making it a promising receptor for small molecule targeted therapy. We hypothesize that poor penetration of the blood-brain barrier by previously tested EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as afateninb, erlotinib, gefitinib, and lapatinib played a role in their limited efficacy. The present study examined the effects of osimertinib (previously known as AZD9291) on EGFRvIII+ GBM models, both in vitro and in vivo. Therefore, a panel of six GBM stem cells (GSCs) expressing EGFRvIII+ was evaluated. The EGFRvIII+ GSC differed in the expression of EGFRvIII and other key genes. The GSC line D317, which expresses high levels of EGFRvIII and has robust tyrosine kinase activity, was selected for assessing osimertinib’s efficacy. Herein, we report that osimertinib inhibits the constitutive activity of EGFRvIII tyrosine kinase with high potency (<100 nM) while also inhibiting its downstream signaling. Further, osimertinib inhibited D317’s growth in vitro and in both heterotopic and orthotopic xenograft models. Additional preclinical studies are warranted to identify EGFRvIII+ GBM’s molecular signature most responsive to osimertinib.
Collapse
Affiliation(s)
- Gustavo Chagoya
- Department of Neurosurgery, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - Shawn G Kwatra
- Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Cory W Nanni
- Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA
| | - Callie M Roberts
- Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA
| | - Samantha M Phillips
- Tri-Institutional MD-PhD Program, Weill Cornell Medical College, The Rockefeller University, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
| | - Sarah Nullmeyergh
- Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA
| | - Samuel P Gilmore
- Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA
| | - Ivan Spasojevic
- Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| | - David L Corcoran
- Genomic and Computational Biology, Duke University Medical Center, Durham, NC, USA
| | - Christopher C Young
- Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA
| | - Karla V Ballman
- Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA
| | | | - Darren A Cross
- IMED Oncology, Global Medical Affairs, AstraZeneca, Cambridge, UK
| | - James M Markert
- Department of Neurosurgery, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - Michael Lim
- Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Mark R Gilbert
- Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Glenn J Lesser
- Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Madan M Kwatra
- Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA.,Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA.,Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| |
Collapse
|
5
|
Ghantasala S, Gollapalli K, Epari S, Moiyadi A, Srivastava S. Glioma tumor proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics 2020; 17:221-232. [PMID: 32067544 DOI: 10.1080/14789450.2020.1731310] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Introduction: Despite being rare cancers, gliomas account for a significant number of cancer-related deaths. Identification and treatment of these tumors at an early stage would greatly improve the therapeutic outcomes. There is an urgent need for diagnostic and prognostic markers, which can identify disease early and discriminate the subtypes of these tumors thereby improving the existing treatment modalities.Areas covered: In this article, we have reviewed published literature on proteomics biomarkers for gliomas and their importance in diagnosis or prognosis. Proteomic studies for the discovery of protein, autoantibody biomarkers, and biological pathway alterations in serum, CSF and tumor biopsies have been discussed in this review.Expert opinion: The rapid development in the field of mass spectrometry and increased sensitivity and reproducibility in assays has led to the identification and quantification of large number of proteins very precisely. Though genomic markers are the prime focus in the classification of gliomas, incorporating protein markers would further improve the existing classification. In this regard, data mining and studies on large cohorts of glioma patients would help in the identification of diagnostic and prognostic markers ultimately translating to the clinics.
Collapse
Affiliation(s)
- Saicharan Ghantasala
- Centre for Research in Nanotechnology and Science, Indian Institute of Technology Bombay, Mumbai, India
| | - Kishore Gollapalli
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.,Department of Pathology & Cell Biology, Columbia University Medical Center, New York, NY, USA.,Center for Motor Neuron Biology & Disease, Columbia University Medical Center, New York, NY, USA
| | - Sridhar Epari
- Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| | - Aliasgar Moiyadi
- Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| | - Sanjeeva Srivastava
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India
| |
Collapse
|
6
|
Kwatra SG, Boozalis E, Huang AH, Nanni C, Khanna R, Williams KA, Semenov YR, Roberts CM, Burns RF, Krischak M, Kwatra MM. Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. MEDICINES 2019; 6:medicines6040114. [PMID: 31835310 PMCID: PMC6963385 DOI: 10.3390/medicines6040114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 11/05/2019] [Accepted: 11/11/2019] [Indexed: 12/29/2022]
Abstract
Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions. Increasingly, the neurokinin-1 receptor (NK1R) antagonist aprepitant is being utilized as an anti-pruritic agent in the treatment of EGFR-inhibitor induced pruritus. Aprepitant is believed to reduce itching by blocking NK1R on the surface of dermal mast cells. However, the effects of aprepitant on human keratinocytes remains unexplored. Methods: Herein, we examine the effects of aprepitant on EGFR stimulation in HaCaT cells using a phosphoproteomic approach including reverse phase protein arrays and Ingenuity Pathway Analysis. Changes in EGFR phosphorylation were visualized using Western blotting and the effect of EGF and aprepitant on the growth of HaCaT cells was determined using the WST-1 Cell Proliferation Assay System. Results: We found that aprepitant increased the phosphorylation of EGFR, as well as 10 of the 23 intracellular proteins phosphorylated by EGF. Analysis of phosphoproteomic data using Ingenuity Pathway Analysis software revealed that 5 of the top 10 pathways activated by EGF and aprepitant are shared. Conclusions: We propose that aprepitant produces its antipruritic effects by partially activating EGFR. Activation of EGFR by aprepitant was also seen in primary human keratinocytes. In addition to itch reduction through partial activation of shared EGFR pathways, aprepitant exerts a dose-dependent cytotoxicity to epithelial cells, which may contribute to its antitumor effects.
Collapse
Affiliation(s)
- Shawn G. Kwatra
- Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; (S.G.K.); (E.B.); (A.H.H.); (R.K.); (K.A.W.)
| | - Emily Boozalis
- Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; (S.G.K.); (E.B.); (A.H.H.); (R.K.); (K.A.W.)
| | - Amy H. Huang
- Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; (S.G.K.); (E.B.); (A.H.H.); (R.K.); (K.A.W.)
| | - Cory Nanni
- Department of Anesthesiology, Duke University, Durham, NC 27710, USA; (C.N.); (C.M.R.); (R.F.B.); (M.K.)
| | - Raveena Khanna
- Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; (S.G.K.); (E.B.); (A.H.H.); (R.K.); (K.A.W.)
| | - Kyle A. Williams
- Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; (S.G.K.); (E.B.); (A.H.H.); (R.K.); (K.A.W.)
| | - Yevgeniy R. Semenov
- Division of Dermatology, Washington University School of Medicine, St. Louis, MI 63110, USA;
| | - Callie M. Roberts
- Department of Anesthesiology, Duke University, Durham, NC 27710, USA; (C.N.); (C.M.R.); (R.F.B.); (M.K.)
| | - Robert F. Burns
- Department of Anesthesiology, Duke University, Durham, NC 27710, USA; (C.N.); (C.M.R.); (R.F.B.); (M.K.)
| | - Madison Krischak
- Department of Anesthesiology, Duke University, Durham, NC 27710, USA; (C.N.); (C.M.R.); (R.F.B.); (M.K.)
| | - Madan M. Kwatra
- Department of Anesthesiology, Duke University, Durham, NC 27710, USA; (C.N.); (C.M.R.); (R.F.B.); (M.K.)
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
- Correspondence:
| |
Collapse
|
7
|
Pediatric brain tumors: Update of proteome-based studies. J Proteomics 2018; 188:41-45. [PMID: 29471057 DOI: 10.1016/j.jprot.2018.02.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Revised: 01/30/2018] [Accepted: 02/09/2018] [Indexed: 11/23/2022]
Abstract
Pediatric brain tumors (PBTs) are the most common solid malignancies in childhood and continue to pose a serious burden to modern societies. Existing treatments impose debilitating effects on the developing child, highlighting the need for molecularly targeted treatments with reduced toxicity, as well as the necessity of markers that reliably assess efficacy of, and tumor response to targeted-therapies of PBTs. On this regard advances in technologies of protein identification and quantification, the large-scale, high-throughput investigation of the proteome, as well the newly-emerging field of "proteogenomics" aim to further our knowledge towards understanding the molecular pathophysiology of PBTs. This mini review article presents all updates on knowledge produced and published during the last years on PBT research derived from "omics" technologies, mainly involving protein research and proteomics.
Collapse
|
8
|
Kwatra MM. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. Curr Cancer Drug Targets 2017; 17:290-296. [PMID: 28029074 DOI: 10.2174/1568009616666161227091522] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Revised: 04/27/2016] [Accepted: 05/17/2016] [Indexed: 01/07/2023]
Abstract
Glioblastoma (GBM) is a deadly brain cancer, and all attempts to control it have failed so far. However, the future looks bright, as we now know the molecular landscape of GBM through the work of The Cancer Genome Atlas (TCGA) program. GBMs exhibit significant inter- and intratumoral heterogeneity, and to control this type of tumor, a personalized approach is required. One target, whose gene is amplified and mutated in a large number of GBMs, is the epidermal growth factor receptor (EGFR). But all attempts to target it have been unsuccessful. We attribute the reason for this failure to the molecular heterogeneity of EGFR in GBM, as well as to the poor brain penetration of previously tested EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs). In this review, we discuss the molecular heterogeneity of EGFR and provide rational preclinical and clinical guidelines for testing AZD9291, a third generation, irreversible EGFR-TKI with both a high affinity for EGFRvIII and excellent brain penetration.
Collapse
Affiliation(s)
- Madan M Kwatra
- Duke University Medical Center, Durham, P.O. Box 3094, NC 27710, United States
| |
Collapse
|
9
|
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 2017; 17:254-268. [PMID: 28104906 DOI: 10.1038/nrc.2016.140] [Citation(s) in RCA: 452] [Impact Index Per Article: 64.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.
Collapse
Affiliation(s)
- Annette T Byrne
- EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | - Denis G Alférez
- EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK
| | - Frédéric Amant
- EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium
- The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
| | - Daniela Annibali
- EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Joaquín Arribas
- EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
- CIBERONC, 08035 Barcelona, Spain
| | - Andrew V Biankin
- EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
| | - Alejandra Bruna
- EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK
| | - Eva Budinská
- EurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic
| | - Carlos Caldas
- EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK
| | - David K Chang
- EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
| | - Robert B Clarke
- EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK
| | - Hans Clevers
- Hubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands
| | - George Coukos
- EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland
| | - Virginie Dangles-Marie
- EurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France
| | - S Gail Eckhardt
- University of Colorado Cancer Center, Aurora, Colorado 80045, USA
| | - Eva Gonzalez-Suarez
- EurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Els Hermans
- EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Manuel Hidalgo
- EurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA
| | - Monika A Jarzabek
- EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | - Steven de Jong
- EurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands
| | - Jos Jonkers
- EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
| | - Kristel Kemper
- EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
| | - Luisa Lanfrancone
- EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy
| | - Gunhild Mari Mælandsmo
- EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway
| | - Elisabetta Marangoni
- EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France
| | - Jean-Christophe Marine
- EurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium
| | - Enzo Medico
- EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy
| | - Jens Henrik Norum
- EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway
| | - Héctor G Palmer
- EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain
| | - Daniel S Peeper
- EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
| | - Pier Giuseppe Pelicci
- EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy
| | - Alejandro Piris-Gimenez
- EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain
| | - Sergio Roman-Roman
- EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France
| | - Oscar M Rueda
- EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK
| | - Joan Seoane
- EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
- CIBERONC, 08035 Barcelona, Spain
| | - Violeta Serra
- EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain
| | - Laura Soucek
- EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Dominique Vanhecke
- EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland
| | - Alberto Villanueva
- EurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - Andrea Bertotti
- EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy
| | - Livio Trusolino
- EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy
| |
Collapse
|
10
|
Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun 2017; 8:14864. [PMID: 28348404 PMCID: PMC5379071 DOI: 10.1038/ncomms14864] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Accepted: 02/06/2017] [Indexed: 01/08/2023] Open
Abstract
Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer proteomes. Here, we employed quantitative proteomics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows positive correlation between expression measurements from transcriptomic and proteomic analyses; further, gene expression-based intrinsic subtypes are largely re-capitulated using non-stromal protein markers. Proteogenomic analysis also validates a number of predicted genomic targets in multiple receptor tyrosine kinases. However, several protein/phosphoprotein events such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1 phosphosites are not readily explainable by genomic analysis, suggesting that druggable translational and/or post-translational regulatory events may be uniquely diagnosed by MS. Drug treatment experiments targeting HER2 and components of the PI3K pathway supported proteogenomic response predictions in seven xenograft models. Our study demonstrates that MS-based proteomics can identify therapeutic targets and highlights the potential of PDX drug response evaluation to annotate MS-based pathway activities. Patient-derived xenografts recapitulate major genomic signatures and transcriptome profiles of their original tumours. Here, the authors, performing proteomic and phosphoproteomic analyses of 24 breast cancer PDX models, demonstrate that druggable candidates can be identified based on a comprehensive proteogenomic profiling.
Collapse
Affiliation(s)
- Kuan-Lin Huang
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Shunqiang Li
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Philipp Mertins
- The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
| | - Song Cao
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Harsha P Gunawardena
- Department of Biochemistry &Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Kelly V Ruggles
- Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, New York 10016, USA
| | - D R Mani
- The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
| | - Karl R Clauser
- The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
| | - Maki Tanioka
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Jerry Usary
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Shyam M Kavuri
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
| | - Ling Xie
- Department of Biochemistry &Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Christopher Yoon
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Jana W Qiao
- The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
| | - John Wrobel
- Department of Biochemistry &Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Matthew A Wyczalkowski
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Petra Erdmann-Gilmore
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Jacqueline E Snider
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Jeremy Hoog
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Purba Singh
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
| | - Beifung Niu
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Zhanfang Guo
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Sam Qiancheng Sun
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Souzan Sanati
- Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Emily Kawaler
- Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, New York 10016, USA
| | - Xuya Wang
- Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, New York 10016, USA
| | - Adam Scott
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Kai Ye
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Department of Genetics, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Michael D McLellan
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Michael C Wendl
- McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Department of Genetics, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Department of Mathematics, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Anna Malovannaya
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA.,Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
| | - Jason M Held
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Department of Anesthesiology, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Michael A Gillette
- The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
| | - David Fenyö
- Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, New York 10016, USA
| | | | - Mehdi Mesri
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
| | - Henry Rodriguez
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
| | - Sherri R Davies
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Charles M Perou
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Cynthia Ma
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - R Reid Townsend
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| | - Xian Chen
- Department of Biochemistry &Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Steven A Carr
- The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
| | - Matthew J Ellis
- Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
| | - Li Ding
- Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,McDonnell Genome Institute, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Department of Genetics, Washington University in St. Louis, St. Louis, Missouri 63108, USA.,Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri 63108, USA
| |
Collapse
|
11
|
Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res 2015; 14:278-86. [PMID: 26685214 DOI: 10.1158/1541-7786.mcr-15-0354] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 11/25/2015] [Indexed: 11/16/2022]
Abstract
UNLABELLED Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xenografts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist. IMPLICATIONS Proteomic characterization of HNSCC PDXs demonstrates potential drivers for model selection and provides a framework for improved utilization of this expanding model system.
Collapse
Affiliation(s)
- Hua Li
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Sarah Wheeler
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Yongseok Park
- Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Zhenlin Ju
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Sufi M Thomas
- Departments of Otolaryngology and Cancer Biology, Kansas University Medical Center, Kansas City, Kansas
| | - Michele Fichera
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Ann M Egloff
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Vivian W Lui
- Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong
| | - Umamaheswar Duvvuri
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. Veterans Affairs Pittsburgh Healthcare System, University Drive Campus, Pittsburgh, Pennsylvania
| | - Julie E Bauman
- Department of Internal Medicine - Hematology/Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Gordon B Mills
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Jennifer R Grandis
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania. Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California.
| |
Collapse
|
12
|
Applicable advances in the molecular pathology of glioblastoma. Brain Tumor Pathol 2015; 32:153-62. [PMID: 26078107 DOI: 10.1007/s10014-015-0224-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 06/01/2015] [Indexed: 12/21/2022]
Abstract
Comprising more than 80% of malignant brain tumors, glioma has proven to be a daunting cause of mortality in a vast majority of the human population. Progressive and extensive research on malignant glioma has substantially enhanced our understanding of glioma cell biology and molecular pathology. Subtypes of glioma such as astrocytoma and oligodendroglioma are currently grouped together into one pathological class, where they show many differences in histology and molecular etiology. This indicates that it may be beneficial to consider a new and radical subclassification. Thus, we summarize recent developments in glioblastoma multiforme (GBM) subtypes, immunohistochemical analyses useful for diagnoses and the biological evaluation and therapeutic implications of gliomas in this review.
Collapse
|